Independent comparison. Not affiliated with Eli Lilly. Not medical advice.
Zepbound vs Mounjaro
Updated 30 March 2026
Zepbound and Mounjaro are the same molecule (tirzepatide), made by the same company (Eli Lilly), in the same factory. The only difference is the label. Zepbound is FDA-approved for weight loss. Mounjaro is FDA-approved for type 2 diabetes. This distinction matters for one reason: insurance coverage.
Weight Loss
FDA-approved Nov 2023
Tirzepatide (dual GIP/GLP-1)
~$1,050/month without insurance
Type 2 Diabetes
FDA-approved May 2022
Tirzepatide (dual GIP/GLP-1)
~$1,050/month without insurance
The Key Difference
Zepbound is labeled for weight loss, which means insurers covering anti-obesity medications will pay for it. Mounjaro is labeled for diabetes, so it is covered for type 2 diabetes but requires off-label prescribing for weight loss. The molecule, dose, pen, and side effects are identical. Your insurance formulary determines which one makes financial sense.
Full Comparison
Every difference (and similarity) between these two brands of tirzepatide.
| Feature | Zepbound | Mounjaro |
|---|---|---|
| Active ingredient | Tirzepatide | Tirzepatide |
| Manufacturer | Eli Lilly | Eli Lilly |
| FDA-approved indication | Chronic weight management (obesity/overweight) | Type 2 diabetes mellitus |
| FDA approval year | November 2023 | May 2022 |
| Mechanism | Dual GIP + GLP-1 receptor agonist | Dual GIP + GLP-1 receptor agonist |
| Dose range | 2.5 mg to 15 mg weekly | 2.5 mg to 15 mg weekly |
| Injection device | Pre-filled single-dose pen (Kwikpen) | Pre-filled single-dose pen (Kwikpen) |
| Monthly cost (no insurance) | ~$1,050 | ~$1,050 |
| Savings card | $25/month (commercially insured) | $25/month (commercially insured) |
| Weight loss insurance coverage | Covered by most commercial plans (on-label) | Off-label only for weight loss. Coverage varies. |
| Diabetes insurance coverage | Not approved for diabetes | Covered by nearly all plans for type 2 diabetes |
| Medicare Part D | Not covered (anti-obesity medication exclusion) | Covered for type 2 diabetes |
| Clinical trial weight loss | 22.5% body weight (SURMOUNT-1, 15 mg) | Same molecule; SURMOUNT data applies |
| Supply status (2026) | Intermittent shortages, improving | Intermittent shortages, improving |
| Off-label use | Sometimes prescribed for diabetes off-label | Frequently prescribed for weight loss off-label |
Cost Calculator
Same molecule, same manufacturer, but your out-of-pocket cost depends on insurance status, pharmacy, and which label your doctor prescribes.
All doses of tirzepatide cost the same per pen. Price does not change with dose strength.
Pharmacy selection only affects cash-pay pricing.
Zepbound (weight loss)
$50
per month
$600
per year
FDA indication: chronic weight management
Mounjaro (diabetes)
$50
per month
$600
per year
FDA indication: type 2 diabetes
With commercial insurance, a typical copay for either is around $50 per month. Actual copay depends on your specific plan formulary and whether prior authorization is approved.
Prices are approximate and vary by location, pharmacy, and insurance plan. Both Zepbound and Mounjaro are manufactured by Eli Lilly and contain identical tirzepatide. The price difference reflects only packaging and labeling.
Why Two Brands for the Same Drug?
The Regulatory Reason
The FDA requires separate approvals for each therapeutic indication. Even though tirzepatide is one molecule, Eli Lilly needed to run separate clinical trial programs to prove it works for weight loss (SURMOUNT trials) and type 2 diabetes (SURPASS trials).
Each approval comes with its own prescribing information, dosing recommendations (though they happen to be identical), and safety data specific to that patient population. The FDA treats these as distinct products even though the active ingredient is the same.
This is not unique to tirzepatide. Semaglutide is sold as Ozempic (diabetes) and Wegovy (weight loss). Liraglutide is sold as Victoza (diabetes) and Saxenda (weight loss). It is standard practice in the pharmaceutical industry.
The Insurance Reason
Health insurers categorize drugs by their approved indication. Diabetes medications and anti-obesity medications sit in different formulary tiers with different coverage rules. By having two brand names, Eli Lilly can negotiate with insurers in both categories simultaneously.
Medicare Part D, for example, is prohibited by law from covering anti-obesity medications. But it does cover diabetes medications. A patient with type 2 diabetes can get tirzepatide covered by Medicare as Mounjaro, but cannot get it covered as Zepbound even though it is the identical drug.
For patients without diabetes who want weight loss treatment, Zepbound provides a clean insurance pathway. Without the weight loss label, insurers would classify off-label Mounjaro prescriptions differently, often denying coverage entirely.
Which One Should You Get?
Get Zepbound if:
- Your primary goal is weight loss (not diabetes treatment)
- Your insurance covers anti-obesity medications
- You have a BMI of 30+ or BMI 27+ with a weight-related condition
- You do not have type 2 diabetes
- Zepbound is in stock at your pharmacy
- Your doctor is writing a new tirzepatide prescription for weight management
Get Mounjaro if:
- You have type 2 diabetes (on-label coverage)
- Your insurance covers Mounjaro but not Zepbound
- You are on Medicare Part D (Mounjaro covered for diabetes, Zepbound is not)
- Mounjaro is in stock but Zepbound is not
- Your doctor already has an active Mounjaro prior authorization
- You have both diabetes and want weight loss (dual benefit from one prescription)